Ceftazidime-avibactam stands up to CRE, but resistance a problem

Intravenous ceftazidime-avibactam successfully treated 59% of carbapenem-resistant Enterobacteriaceae (CRE) infections, and 76% of patients remained alive at 30 days, according to a retrospective...
Source: Hospitalist News - Category: Hospital Management Source Type: research